Healthcare Resource Use in Commercially- and Medicaid-Insured Infants, Toddlers, and Children Diagnosed With Invasive Meningococcal Disease in the United States
Author(s)
Oscar Herrera-Restrepo, PhD1, Elizabeth Packnett, MPH2, Megan Richards, PhD, MPH2, Elise Kuylen, PhD3, Tosin Olaiya, MBChB, MSc1, Lindsay Landgrave, PharmD1, Andrew G Allmon, DrPH4, Linda Niccolai, PhD, ScM5;
1GSK, Philadelphia, PA, USA, 2Merative, Ann Arbor, MI, USA, 3GSK, Wavre, Belgium, 4GSK, Durham, NC, USA, 5Yale School of Public Health, New Haven, CT, USA
1GSK, Philadelphia, PA, USA, 2Merative, Ann Arbor, MI, USA, 3GSK, Wavre, Belgium, 4GSK, Durham, NC, USA, 5Yale School of Public Health, New Haven, CT, USA
Presentation Documents
OBJECTIVES: To describe all-cause healthcare resource utilization (HCRU) among infants (<1 year), toddlers (1-4 years), and children (5-10 years) diagnosed with invasive meningococcal disease (IMD) in the United States (US).
METHODS: This retrospective study analyzed claims data of commercially- and Medicaid-insured individuals from 01/01/2005 to 12/31/2022. Individuals with IMD were identified through inpatient admissions with a primary IMD diagnosis and matched 1:5 with individuals without IMD. Toddlers and children were required to have six months of continuous enrollment prior to index. A variable follow-up period was used to assess all-cause HCRU, which was calculated using diagnosis/procedure codes and reported as per-patient per-month (PPPM; mean [standard deviation]).
RESULTS: In the commercial cohort (N>29.1 million), 21 infants, 19 toddlers, and 21 children diagnosed with IMD were included. In the Medicaid cohort (N>17.9 million), 115 infants, 35 toddlers, and 13 children diagnosed with IMD were included. Median follow-up length (across insurance cohort, age group, and IMD status) ranged from 244.0-1,161.0 days. Individuals with IMD had significantly longer inpatient stays than matched individuals across insurance cohorts (1.50 [3.67] vs. 0.02 [0.10] days; all p≤0.001). The number of office visits was significantly higher for individuals with IMD than matched individuals (commercial: 1.11 [0.91] vs. 0.54 [0.45] in infants, 0.46 [0.40] vs. 0.22 [0.20] in toddlers, and 0.53 [0.44] vs. 0.17 [0.25] in children; Medicaid: 0.53 [0.38] vs. 0.37 [0.40] in infants, 0.48 [0.48] vs. 0.19 [0.29] in toddlers, and 0.43 [0.32] vs. 0.14 [0.23] in children; all p<0.001). Emergency visits were significantly more common among infants with IMD than matched individuals (commercial: 0.06 [0.11] vs. 0.02 [0.04]; Medicaid: 0.12 [0.15] vs. 0.06 [0.13]; all p≤0.004).
CONCLUSIONS: Preventing IMD in early childhood may help reduce HCRU, which can be considerable, address inequalities associated with insurance, and ease financial burdens on families and healthcare systems. Funding: GSK (VEO-000995).
METHODS: This retrospective study analyzed claims data of commercially- and Medicaid-insured individuals from 01/01/2005 to 12/31/2022. Individuals with IMD were identified through inpatient admissions with a primary IMD diagnosis and matched 1:5 with individuals without IMD. Toddlers and children were required to have six months of continuous enrollment prior to index. A variable follow-up period was used to assess all-cause HCRU, which was calculated using diagnosis/procedure codes and reported as per-patient per-month (PPPM; mean [standard deviation]).
RESULTS: In the commercial cohort (N>29.1 million), 21 infants, 19 toddlers, and 21 children diagnosed with IMD were included. In the Medicaid cohort (N>17.9 million), 115 infants, 35 toddlers, and 13 children diagnosed with IMD were included. Median follow-up length (across insurance cohort, age group, and IMD status) ranged from 244.0-1,161.0 days. Individuals with IMD had significantly longer inpatient stays than matched individuals across insurance cohorts (1.50 [3.67] vs. 0.02 [0.10] days; all p≤0.001). The number of office visits was significantly higher for individuals with IMD than matched individuals (commercial: 1.11 [0.91] vs. 0.54 [0.45] in infants, 0.46 [0.40] vs. 0.22 [0.20] in toddlers, and 0.53 [0.44] vs. 0.17 [0.25] in children; Medicaid: 0.53 [0.38] vs. 0.37 [0.40] in infants, 0.48 [0.48] vs. 0.19 [0.29] in toddlers, and 0.43 [0.32] vs. 0.14 [0.23] in children; all p<0.001). Emergency visits were significantly more common among infants with IMD than matched individuals (commercial: 0.06 [0.11] vs. 0.02 [0.04]; Medicaid: 0.12 [0.15] vs. 0.06 [0.13]; all p≤0.004).
CONCLUSIONS: Preventing IMD in early childhood may help reduce HCRU, which can be considerable, address inequalities associated with insurance, and ease financial burdens on families and healthcare systems. Funding: GSK (VEO-000995).
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE80
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Pediatrics, STA: Vaccines